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Background-—Stroke is a leading cause of death in the world. In >80% of strokes, the initial acute phase of ischemic injury is due
to the occlusion of a blood vessel resulting in severe focal hypoperfusion, excitotoxicity, and oxidative damage. Interferon-b (IFNb),
a cytokine with immunomodulatory properties, was approved by the US Food and Drug Administration for the treatment of
relapsing-remitting multiple sclerosis for more than a decade. Its anti-inﬂammatory properties and well-characterized safety proﬁle
suggest that IFNb has therapeutic potential for the treatment of ischemic stroke.
Methods and Results-—We investigated the therapeutic effect of IFNb in the mouse model of transient middle cerebral artery
occlusion/reperfusion. We found that IFNb not only reduced infarct size in ischemic brains but also lessened neurological deﬁcits in
ischemic stroke animals. Further, multiple molecular mechanisms by which IFNb modulates ischemic brain inﬂammation were
identiﬁed. IFNb reduced central nervous system inﬁltration of monocytes/macrophages, neutrophils, CD4+ T cells, and cd T cells;
inhibited the production of inﬂammatory mediators; suppressed the expression of adhesion molecules on brain endothelial cells;
and repressed microglia activation in the ischemic brain.
Conclusions-—Our results demonstrate that IFNb exerts a protective effect against ischemic stroke through its anti-inﬂammatory
properties and suggest that IFNb is a potential therapeutic agent, targeting the reperfusion damage subsequent to the treatment
with tissue plasminogen activator. ( J Am Heart Assoc. 2016;5:e002610 doi: 10.1161/JAHA.115.002610)
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S troke is a leading cause of death and results inpermanent disability in up to 30% of survivors. In >80%
of strokes, the initial acute phase of ischemic injury is due to
the occlusion of a blood vessel, resulting in severe focal
hypoperfusion, excitotoxicity, and oxidative damage.1–3 The
inﬂammatory response that characterizes the subacute
phase of ischemia is initiated by resident microglia
(MG) and peripheral inﬂammatory cells inﬁltrating the region
surrounding the infarct core and leading to secondary
neurodegeneration.4
The initiation of cerebral ischemia is associated with
blood–brain barrier (BBB) breakdown, extravasation of plasma
protein and bioactive phospholipids, rapid activation of
resident MG resulting in migration to the ischemic site, and
the release of endogenous nitric oxide, proinﬂammatory
cytokines such as tumor necrosis factor (TNF)a and inter-
leukin (IL)-1b, and chemokines such as CCL2 and CCL3.4,5
TNFa induces the upregulation of adhesion molecules on
cerebral endothelial cells and, in conjunction with CCL3 and
CXCL3, promotes the adhesion and directed transmigration of
blood-borne leukocytes. This results in inﬁltration of periph-
eral immune cells including neutrophils, monocytes/macro-
phages, and T cells into the infarcted tissue. Invading
monocytes/macrophages were detected in the ischemic
brain as early as day 1, reaching a peak on day 3. The
numbers of neutrophils and T lymphocytes including CD4+ T
cells, natural killer T cells, and cd T cells were increased on
day 3 and declined on day 7 postinjury.1,6
Current clinical therapies using thrombolytic agents are
limited by temporal restrictions and do not prevent the
secondary, inﬂammation-related central nervous system
(CNS) damage. Therefore, the development of new anti-
inﬂammatory therapies in ischemic stroke is necessary and
urgent. Interferon-b (IFNb), a cytokine with immunomodula-
tory properties, was approved by US Food and Drug
Administration for the treatment of relapsing-remitting mul-
tiple sclerosis for more than a decade.7,8 Its anti-inﬂammatory
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properties,9–13 and well-characterized safety proﬁle suggest
that IFNb has therapeutic potential for the treatment of
ischemic stroke.
In this study, we evaluated the therapeutic effect of IFNb
in the mouse model of transient middle cerebral artery
occlusion/reperfusion (MCAO/R). Our results show that IFNb
not only reduced infarct size in ischemic brains but also
lessened neurological deﬁcits in ischemic stroke animals.
Moreover, the reduction of brain infarct in the IFNb-treated
mice was associated with decreased inﬁltration of mono-
cytes/macrophages, neutrophils, cd T cells, and CD4+ T
cells. Further investigation of molecular mechanisms
revealed that IFNb treatment inhibited the production of
inﬂammatory mediators, suppressed the expression of
adhesion molecules, and repressed the activation of MG in
the ischemic brain. Thus, our results suggest that IFNb has a
protective effect in ischemic stroke through its anti-
inﬂammatory properties.
Materials and Methods
Mice
C57BL/6 wild-type mice were obtained from Jackson Labo-
ratories. Ifnar1tm1Agt/Mmjax (Ifnar1/ mice) were purchased
from Mutant Mouse Regional Resources Center. All mice were
kept and bred in the animal facility of Indiana University
School of Medicine–Fort Wayne. All animal procedures in this
study were conducted in strict compliance with the National
Institutes of Health “Guide for the Care and Use of Laboratory
Animals” and approved by Purdue Animal Care and Use
Committee.
Reagents
Lipopolysaccharide (LPS; Escherichia coli O55:B5) and triph-
enyltetrazolium chloride (TTC) were purchased from Sigma-
Aldrich. IFNb was purchased from PBL Interferon Source.
Recombinant murine granulocyte-macrophage colony-stimu-
lating factor and TNFa were purchased from Peprotech Inc.
Prostaglandin E2 was purchased from Cayman Chemical
Company. Alexa Fluor 488–conjugated anti-mouse CD4
(clone: RM4-5), CD45 (clone: 30-F11), and CD31 (clone:
MEC13.3); phycoerythrin-conjugated anti-mouse CD3 (clone:
145-2C11) and CD11b (clone: M1/70); phycoerythrin/Cy7–
conjugated anti-mouse TCRcd (clone: GL3); and Allophyco-
cyanin-conjugated anti-mouse CD54/intercellular adhesion
molecule (ICAM)-1 (clone: YN1/1.7.4), F4/80 (clone: BM8),
and Ly6G (clone: 1A8) were purchased from BioLegend.
Fluorescein isothiocyanate–conjugated anti-mouse CD62P/
P-selectin (clone: RB40.34) and phycoerythrin-conjugated
anti-mouse CD62E/E-selectin (clone: 10E9.6) were pur-
chased from BD PharMingen. Alexa Fluor 488–cojugated
donkey anti-rabbit IgG (H+L) was purchased from Life
Technologies. Rabbit polyclonal anti-mouse Iba1 was pur-
chased from Wako Pure Chemical Industries, Ltd.
Mouse Focal Brain Ischemia Model
Male mice, aged 8 to 12 weeks and weighing 20 to 30 g,
were subjected to MCAO/R for induction of focal brain
ischemia. Brieﬂy, the mice were initially anesthetized with
2% and maintained on 1.5% isoﬂurane in a mixture of 70% air
and 30% O2 with the use of a vaporizer. Body temperature
was maintained at 37°C with a warming lamp and heating
pad. Cerebral blood ﬂow was measured before, during, and
after ischemia by using laser Doppler ﬂowmetry at the
parietal bone (2 mm posterior and 3 mm lateral from
bregma). Each mouse’s resting CBF value was taken as
the baseline value, and changes in cerebral blood ﬂow after
the induction of brain ischemia were expressed as percent-
ages of the resting value. The right common carotid artery
and the right external carotid artery were exposed through a
midline neck incision. The external carotid artery was
dissected distally, ligated, and coagulated along with the
terminal lingual and maxillary artery branches. A minimal
incision was made in the external carotid artery stump, with
iridectomy scissors. After the incision, occlusion of the
middle cerebral artery was performed by using a silicon-
coated 6-0 nylon monoﬁlament (Doccol Corp; 0.23 mm). The
distance from the suture tip to the right common carotid
artery bifurcation was 9 mm. During right middle cerebral
artery occlusion, a reduction in cerebral blood ﬂow of >60%
was conﬁrmed with laser Doppler ﬂowmetry. Forty minutes
after MCAO, the ﬁlament was withdrawn to allow blood ﬂow
reperfusion. After surgery, mice recovered in cages, where
the temperature was kept at 34°C for 1 hour. For IFNb
treatment, 10 000 U of recombinant murine IFNb suspended
in 100 lL of PBS were administered via intravenous
injection to MCAO/R mice. The concentration of IFNb used
in this study was based on the previous study established in
experimental autoimmune encephalomyelitis models.14–16
Infarct Volume Measurements
Forty-eight hours after reperfusion, the mice were sacriﬁced
and their brains were removed. Next, 2-mm coronal slices
were obtained with use of a rodent brain matrix. The
sections were stained with 1% TTC for 10 minutes at 37°C
for measurements of infarct volume. Infarction volume was
calculated according to Swanson and colleagues
to compensate for brain swelling in the ischemic hemi-
sphere17 and analyzed by using ImageJ (National Institutes
of Health).
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Neurological Assessment
Neurological function was evaluated by using a 6-point score
as previously described18 and performed at 48 hours after
reperfusion. An expanded 6-point scale is used (0, normal;
score 1, mild circling behavior with or without inconsistent
rotation when picked up by the tail, <50% attempts to rotate
to the contralateral side; score 2, mild consistent circling,
>50% attempts to rotate to contralateral side; score 3,
consistent strong and immediate circling, the mouse holds a
rotation position for more than 1 to 2 seconds, with its nose
almost reaching its tail; score 4, severe rotation progressing
into barreling, loss of walking, or righting reﬂex; and score 5,
comatose or moribund).
Mononuclear Cell Isolation and Fluorescence-
Activated Cell Sorter Analysis
Mice were perfused with ice-cold PBS; brains were freed from
meninges; and the olfactory bulb and cerebellum were
discarded. The harvested brains were separated into hemi-
spheres. The brain was homogenized with 19 Hanks balanced
saline solution buffer and ﬁltered through a 40-lm nylon cell
strainer. After centrifugation, cells were resuspended in
10 mL of 30% Percoll and underlayered with 5 mL of 70%
Percoll. The samples were then centrifuged at room temper-
ature for 25 minutes at 1000g. The cells at the 30:70
interface were isolated, washed, and stained with anti-CD45,
anti-CD11b, and anti-Ly6G, followed by ﬂuorescence-acti-
vated cell sorter (FACS) analysis of 20 000 counts per sample.
For CD4+ T-cell and cd T-cell analysis, the cells collected from
the 30:70 interface were stained with anti-CD3, anti-CD4, and
anti-TCRcd, followed by FACS analysis.
Real-Time Reverse Transcription–Polymerase
Chain Reaction
Expression of different genes was detected by quantitative
polymerase chain reaction as previous described.19 The
sequences of primers are as following: E-selectin: 50-CATCC
TGCAGTGGTCATGGT-30 and 50-GCAAGTCACAGCTTGCTCAC30;
ICAM-1: 50-CACGTGCTGTATGGTCCTCG-30 and 50-TAGGAGAT
GGGTTCCCCCAG-30; CXCL3: 50-CCCAGACAGAAGTCATA
GCCA-30 and 50-GTGAGGGGCTTCCTCCTTTC-30; CCL3: 50-CC
CAGCCAGGTGTCATTTTC-30 and 50-CTCAAGCCCCTGCTCTAC
AC-30; MMP-9: 50-AAAACCTCCAACCTCACGGA-30 and 50-G
CGGTACAAGTATGCCTCTGC-30; IL-1b: 50-CCCTGCAGCTGGA
GAGTGTGGA-30 and 50-TGTGCTCTGCTTGTGAGGTGCTG-30; IL-
6: 50-TCCTCTCTGCAAGAGACTTCCATCC-30 and 50-GGGAAG
GCCGTGGTTGTCACC-30; IL-23p19: 50-TGCTGGATTGCAGAGCA
GTAA-30 and 50-GCATGCAGAGATTCCGAGAGA-30; TNFa: 50-AT
GGCCTCCCTCTCATCAGT-30 and 50-CTTGGTGGTTTGCTACGA
CG-30; and IL-12p40: 50-TGGTTTGCCATCGTTTTGCTG-30 and
50-ACAGGTGAGGTTCACTGTTTCT-30.
Cell Culture
Mouse brain endothelial cells (bEnd.3; American Type Culture
Collection) were grown in 25-cm2 ﬂasks. Once the cells were
grown to conﬂuence, they were trypsinized and seeded onto
tissue culture plates. The cells were subjected to FACS
analysis for brain endothelial cell–speciﬁc marker CD31
(platelet endothelial cell adhesion molecule-1) expression.
More than 94% of cells were positive for platelet endothelial
cell adhesion molecule-1 expression.
MG were generated from neonatal mice. In brief, cerebral
cortical cells from 1- to 2-day-old mice were dissociated and
plated in 75-cm2 culture ﬂasks. The medium was removed and
replenished with medium containing 10 ng/mL granulocyte-
macrophage colony-stimulating factor on days 5 and 10 after
plating. On day 15, MG were harvested by shaking the ﬂasks
at 300 rpm at 37°C for 30 minutes. More than 90% of
harvested cells were positive for CD11b and F4/80 expres-
sion by FACS analysis.
Immunohistochemistry
Mice were transcardiacally perfused with PBS and brains were
extracted. Coronal brain blocks (2 mm) were cut, postﬁxed in
4% paraformaldehyde, and cryoprotected in 6% followed by
30% sucrose-PBS. Brain blocks were subsequently embedded
in optimal cutting temperature compound and frozen with
isopentane cooled by liquid nitrogen. Serial 15-lm frozen
sections were cut in a cryostat, mounted on superfrost plus
slides, and stored at 20°C until staining. After washing with
PBS, slides were permeabilized with 0.5% Triton X-100/PBS
for 30 minutes and then incubated with blocking solution
(0.25% Triton X-100/PBS, 3% normal donkey serum in PBS)
for 1 hour at room temperature. The primary antibody (rabbit
anti-Iba1, 1:800; Wako) was added on slides for 2-hour
incubation at room temperature. Slides were washed with PBS
and incubated with ﬂuorescent secondary antibody (donkey
anti-rabbit IgG, 1:400 Alexa Fluor 488; Invitrogen) for 1 hour
at room temperature. After washing with PBS, slides were
mounted and coverslipped with ProLong Gold anti-fade
mountant with DAPI (Invitrogen). Brain regions of interest
were deﬁned in relation to anatomical landmarks by using the
Franklin and Paxinos Mouse Brain in Stereotaxic Guidance. The
Nuance FX multispectral imaging system and Nuance soft-
ware (PerkinElmer) were used for image collection and
analysis. Each stained section was processed under identical
gain and laser power setting. Two or 3 different sections from
each mouse at the bregma 0.98 to 0.86 mm were stained and
analyzed (n=6 mice in the vehicle- and IFNb-treated groups).
DOI: 10.1161/JAHA.115.002610 Journal of the American Heart Association 3
Anti-inﬂammatory Effects of IFNb in Ischemic Stroke Kuo et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Activation of MG was evaluated on the basis of Iba1 intensity
exceeding the set threshold and of cellular morphology. Image
of single-cell morphology was acquired by using the Fluoview
FV10i confocal microscope (Olympus) and analyzed with the
use of ImageJ.
Immunocytochemistry
MG were ﬁxed in 2% paraformaldehyde for 15 minutes at
room temperature. After being washed with PBS, cells were
permeabilized with 0.3% Triton X-100/PBS for 10 minutes
and then blocked in 3% normal donkey serum for 30 min-
utes at room temperature. Cells were incubated with primary
antibody (rabbit anti-Iba1, 1:800) for 1 hour at room
temperature. After being washed with PBS, cells were
incubated with ﬂuorescent secondary antibody (donkey
anti-rabbit, 1:400 Alexa Fluor 488) for 1 hour at room
temperature. After being washed with PBS, cells were
coverslipped with ProLong Gold antifade mountant with
DAPI (Invitrogen). Confocal images were acquired by using
Fluoview FV10i confocal microscope (Olympus) and analyzed
by using ImageJ.
Statistical Analysis
Results are given as meanSEM. Comparisons between 2
groups were done by using the paired t test, whereas
comparisons between multiple groups were done by using 1-
way ANOVA followed by Bonferroni post hoc test. For in vivo
study with the groups containing ≥7 mice, a Shapiro–Wilk
normality test was performed to ensure a normal distribution
of the data. For neurological scores, comparisons between 2
groups were calculated with use of the v2 test of proportions.
For quantitative cell counts of activated MG and measure-
ments of MG soma size in the immunohistochemistry brain
samples, comparisons between multiple groups were calcu-
lated with the use of Kruskal–Wallis test followed by Dunn
post hoc test. Statistical signiﬁcance was determined with P
values <0.05.
Results
IFNb Confers a Protective Effect Against Ischemic
Stroke
In this study, we used the mouse MCAO/R model. Physio-
logical parameters for the MCAO/R mice are listed in Table.
All mice had similar body temperatures and blood oxygen
levels during surgery, and a blood ﬂow drop of >60% between
the initial reading and after suture insertion. We ﬁrst
evaluated whether pretreatment with IFNb would offer a
protective effect in ischemic stroke. Mice were administered
IFNb or vehicle 3 hours before the induction of MCAO/R.
Forty-eight hours after reperfusion, infarct volumes were
assessed by using TTC staining. Pretreatment with IFNb
signiﬁcantly reduced the infarct volume (5.40.8 IFNb versus
15.21.9 vehicle; Figure 1A and 1B). Lower neurological
scores were also observed in IFNb-treated mice (1.20.2
IFNb versus 2.10.3 vehicle; Figure 1C). We then evaluated
the therapeutic effect of IFNb treatment in ischemic stroke.
IFNb was administrated to MCAO/R mice 3 hours after
reperfusion, and the ischemic brain infarction was accessed
by using TTC at 48 hours postreperfusion. Similar to the
results of IFNb pretreatment, IFNb posttreatment reduced
infarct volumes (7.30.8 IFNb versus 15.91.2 vehicle;
Figure 1D and 1E) as well as the neurological score (1.40.2
IFNb versus 2.20.3 vehicle; Figure 1F). The protective effect
of IFNb in ischemic stroke is mediated through type I IFN
receptor because IFNb failed to reduce infarct volume in
Ifnar1/ MCAO/R mice compared with vehicle-treated
controls (Figure 1G and 1H). Altogether, our results demon-
strated IFNb attenuated ischemic brain infarct and lessened
ischemia-induced neurological deﬁcits, suggesting its thera-
peutic potential for ischemic brain injury.
IFNb Suppresses Inﬂammation in Ischemic Brains
Ischemia-induced CNS inﬂammation exerts a fundamental role
in stroke pathophysiology and promotes infarct formation in the
Table. Physiological Parameters of Mice During MCAO/R
Strain Parameter Body Weight, g
During MCAO
Body Temperature (°C) Blood O2 (%) Drop in Doppler Signal (%)
C57BL/6 Wild-type Vehicle (N=15) 24.81.7 37.20.3 97.21.7 72.510.8
IFNb (post 3h) (N=15) 25.71.5 37.10.2 97.60.7 78.79.2
Vehicle (N=10) 27.84.3 37.20.2 97.70.6 80.77.1
IFNb (pre 3h) (N=10) 26.61.9 37.20.2 97.51.0 74.46.7
Ifnar1/ Vehicle (N=8) 23.21.1 37.30.2 97.21.4 72.28.8
IFNb (post 3h) (N=8) 23.21.3 37.30.2 97.11.0 79.64.6
IFN indicates interferon; MCAO/R, middle cerebral artery occlusion/reperfusion; Post 3h, 3 hours after reperfusion; Pre 3h, 3 hours before MCAO/R induction.
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Figure 1. Interferon (IFN)b-treated middle cerebral artery occlusion/reperfusion (MCAO/
R) mice are protected from cerebral ischemic injury. C57BL/6 mice (n=10/group)
intravenously treated with vehicle or IFNb were subjected to MCAO/R 3 hours later. A,
Forty-eight hours after MCAO/R, mice were sacriﬁced, and ischemic brains were harvested
and sliced (2 mm), followed by TTC staining. B, The infarct size of ischemic brains of vehicle-
and IFNb-pretreated mice was measured. C, Neurological scores of vehicle- and IFNb-
treated MCAO/R mice were evaluated. C57BL/6 mice (n=15/group) subjected to MCAO/R
were treated with vehicle or IFNb 3 hours after reperfusion. D, Ischemic brains of vehicle-
and IFNb-treated MCAO/R mice were subjected to TTC staining, and 5 representative TTC-
stained samples are shown. E and F, The infarct volume was measured and the neurological
scores were determined. Type I IFN receptor–deﬁcient (Ifnar1/) mice (n=8/group) were
subjected to MCAO/R and treated with vehicle or IFNb 3 hours after reperfusion. At
48 hours later, the mice were sacriﬁced, and brains were sliced (2 mm), followed by TTC
staining. G, Two representative TTC-stained samples are shown. H, The infarct volume for
vehicle- and IFNb-treated Ifnar1/ MCAO mice was measured. ***P<0.001, N.S., no
signiﬁcance by paired t test. aP<0.05 by the v2 test.
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ischemic brain.20–22 Because IFNb markedly attenuated infarct
size 48 hours post injury (Figure 1), we investigated whether
IFNb inhibits the production of inﬂammatory cytokines in the
ischemic brains at an early phase (24 hours post injury). We
collected ischemic brains from MCAO/R mice 24 hours after
reperfusion and extracted RNA followed by quantitative PCR
analysis for inﬂammatory cytokine expression. Our results show
that inﬂammatory cytokines, including IL-1b, IL-6, IL-23p19, and
TNFa, were upregulated in the ipsilateral hemispheres of
vehicle-treated MCAO/R mice and that IFNb treatment signif-
icantly reducedproinﬂammatory cytokine expression (Figure 2).
Thus, our results suggest that IFNb-mediated reduction of
inﬂammatory cytokine expression in the ischemic brain might
contribute to its protective effects in ischemic stroke.
IFNb Suppresses MG Activation in Ischemic
Brains
In response to ischemic injury, rapidly activated MG are the
major source of inﬂammatory mediators that cause cytotoxic
effects in the ischemic brain.22,23 Because the upregulation
of inﬂammatory cytokines in the ischemic brain was
inhibited by IFNb (Figure 2), we speculated that IFNb might
suppress MG activation. Brain slices were prepared from 24-
hour ischemic brains followed by Iba1 staining. Cerebral
ischemia signiﬁcantly increased Iba1 expression in the
cortex of ipsilateral, but not contralateral hemispheres
(Figure 3A, top). When comparing MG activation in the
ipsilateral hemispheres of vehicle- and IFNb-treated MCAO/R
mice, IFNb treatment markedly suppressed Iba1 expression
(Figure 3A, right). In addition, confocal images showed a
round and amoeboid morphology with shorter processes and
enlarged soma in vehicle controls, suggestive of activated
MG, whereas MG from IFNb-treated animals displayed
ramiﬁed morphology with long branching processes and
smaller soma, indicative of a resting phenotype (Figure 3A,
insets). Quantitative analysis of MG activation revealed a
signiﬁcant reduction in Iba1+ cell numbers (Figure 3B, top)
as well as soma size (Figure 3B, bottom) for IFNb-treated
MCAO/R mice.
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Figure 2. Interferon (IFN)b inhibits the production of proinﬂammatory cytokines in the ischemic brain.
Ipsilateral and contralateral brain hemispheres from sham control, vehicle-, and IFNb-treated middle
cerebral artery occlusion/reperfusion (MCAO/R) mice (n=7/group) were harvested 24 hours after
reperfusion. mRNA expression of interleukin (IL)-1b, IL-6, IL-23p19, and TNF-a was determined by
quantitative polymerase chain reaction (Q-PCR). Data are presented as the group meanSEM. **P<0.01,
***P<0.001 by 1-way ANOVA with Bonferroni’s multiple comparison test.
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Figure 3. Interferon (IFN)b suppresses microglia (MG) activation in the ischemic brain as well as in
primary MG. A, Representative images of Iba1-positive MG in the contralateral and ipsilateral cortex of
vehicle-treated and in the ipsilateral cortex of sham and IFNb-treated middle cerebral artery occlusion/
reperfusion (MCAO/R) mice. Insets: confocal images of Iba1-positive MG. DAPI (blue) stains for cell
nucleus. Scale bar, 50 lm. B, Quantitative cell counts of activated MG and measurements of MG soma
size in the ipsilateral cortex of sham (n=3), vehicle- (n=6), and IFNb-treated (n=6) MCAO/R mice. Data
are presented as the group meanSEM. *P<0.05 by Kruskal–Wallis test with post hoc Dunn multiple
comparison test. C and D, Primary MG were pretreated with IFNb for 1 hour followed by liposaccharide
(LPS) treatment. Twenty hours after LPS stimulation, cells were ﬁxed and subjected to Iba1
immunocytochemistry staining. Representative confocal images of Iba1-labeled (green) primary MG.
DAPI-stained cell nuclei are depicted in blue. Scale bar, 20 lm (C). At 1, 3, or 5 hours after LPS
stimulation, cells were collected and subjected to RNA extraction followed by quantitative polymerase
chain reaction (Q-PCR) for IL-1b and IL-12p40 expression (D). Data are the representative results of 3
independent experiments. *P<0.05, ***P<0.001 by 1-way ANOVA with Bonferroni’s multiple
comparison test.
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Figure 4. Interferon (IFN)b interferes with the recruitment of inﬂammatory peripheral immune cells into the ischemic
brain. C57BL/6 mice (n=7/group) subjected to middle cerebral artery occlusion/reperfusion (MCAO/R) were treated
with vehicle or IFNb 3 hours after reperfusion. Forty-eight hours later, ischemic brains of vehicle and IFNb-treated
MCAO/R mice and sham control brains were harvested. The contralateral and ipsilateral hemispheres of vehicle- and
IFNb-treated mice as well as sham control brains were subjected to mononuclear cell isolation by 30%:70% Percoll
gradient. Cells were then stained with antibodies against CD45, CD11b, and Ly6G. A, top, central nervous system–
inﬁltrating immune cells (CD45hiCD11b+) and MG (CD45intCD11b+). A, bottom, neutrophils (CD11b+Ly6G+). B and C,
Numbers and percentages of peripheral inﬁltrating cells (CD45hiCD11b+) and neutrophils (CD11b+Ly6G+) were
determined. ***P<0.001 by 1-way ANOVA with Bonferroni’s multiple comparison test.
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Figure 5. Interferon (IFN)b suppresses CNS inﬁltration of CD4+ T and cd T cells in the
ischemic brain. A, C57BL/6 mice (n=8/group) subjected to middle cerebral artery
occlusion/reperfusion (MCAO/R) were treated with either vehicle or IFNb 3 hours after
reperfusion. Ninety-six hours later, mice were sacriﬁced, and ischemic brains were
harvested and sliced (2 mm), followed by TTC staining. B, The infarct volume of ischemic
brains was measured. ***P<0.001 by paired t test. C, Mononuclear cells were isolated
from the contralateral and ipsilateral hemispheres of vehicle- and IFNb-treated mice as
well as sham control brains. Cells were stained with antibodies against CD3, CD4, and
TCRcd. CD4+ T and cd T cells were determined as CD3+CD4+ and CD3+TCRcd+,
respectively. D, Numbers of CD3+CD4+ T cells and CD3+TCRcd+ T cells were determined.
*P<0.05, **P<0.01, ***P<0.001 by 1-way ANOVA with Bonferroni’s multiple compar-
ison test.
DOI: 10.1161/JAHA.115.002610 Journal of the American Heart Association 9
Anti-inﬂammatory Effects of IFNb in Ischemic Stroke Kuo et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
The inhibitory effect of IFNb on MG activation was
further conﬁrmed in primary MG in vitro. Cells were treated
with LPS in the presence or absence of IFNb for 24 hours
followed by Iba1 staining. MG treated with LPS had
increased Iba1 expression and changed morphology from
ramiﬁed to the amoeboid phenotype. IFNb suppressed LPS-
induced Iba1 expression and preserved the ramiﬁed
phenotype similar to the phenotype of resting MG (MED;
Figure 3C). In addition, IFNb inhibited LPS-induced IL-1b
and IL-12p40 expression (Figure 3D). Taken together, our
results demonstrate that IFNb suppressed ischemia-induced
MG activation in vivo and LPS-induced MG activation
in vitro.
IFNb Diminishes Peripheral Immune Cell
Inﬁltration Into the Ischemic Brain
Cerebral ischemia followed by reperfusion promotes CNS
inﬁltration of peripheral immune cells including neutrophils,
monocytes/macrophages, and T cells, leading to secondary
brain injury characterized by enlarged brain infarction.22,24
To investigate whether IFNb affects inﬂammatory cell
inﬁltration, we characterized inﬁltrating cell populations in
the ischemic brains of vehicle- and IFNb-treated MCAO/R
mice at 48 hours after reperfusion. We observed a
signiﬁcant increase in cell numbers of CD45hiCD11b+
monocytes/macrophages and CD11b+Ly6G+ neutrophils in
ipsilateral hemispheres of vehicle-treated mice, with only a
few inﬁltrating cells in the contralateral hemispheres
(Figure 4A through 4C). We then compared cell inﬁltrates
in the ischemic brains of vehicle- and IFNb-treated animals.
Our results show signiﬁcantly lower numbers of inﬁltrating
CD45hiCD11b+ monocytes/macrophages and CD11b+Ly6G+
neutrophils in the ipsilateral hemispheres of IFNb-treated
mice (Figure 4B and 4C). In contrast to the CD45hiCD11b+
inﬁltrating peripheral immune cells, IFNb did not affect the
numbers of CD45intCD11b+ resident MG (results not
shown).
Both CD4+ T and cd T cells have been reported to play a
pathogenic role in ischemic stroke.25,26 In line with previous
study,26 we found increased numbers of CD4+ T and cd T cells
in the ischemic brains and enlarged infarct size on day 4 post
injury. More importantly, IFNb treatment diminished both
CD4+ T- and cd T-cell numbers (Figure 5C and 5D) and
attenuated infarct size (Figure 5A and 5B). Taken together,
our results demonstrate that IFNb treatment suppressed the
inﬁltration of monocytes/macrophages, neutrophils, and
CD4+ T and cd T cells, suggesting that inhibition of CNS
inﬁltration of inﬂammatory cells represents one of the
mechanisms for the protective effect of IFNb in ischemic
stroke.
IFNb Inhibits Adhesion Molecule Expression in
the Ischemic Brain
The inﬂux of inﬂammatory cells into ischemic brains is
facilitated by adhesion molecules expressed on the surface of
brain endothelial cells. E-selectin, P-selectin, ICAM-1, and
vascular cell adhesion molecule (VCAM)-1 were reported to be
upregulated in brain endothelial cells within hours of reper-
fusion in the MCAO/R model.27,28 Our results also demon-
strate a marked increase in ICAM-1 and E-selectin in the
ipsilateral hemispheres at 24 hours post ischemia (Fig-
ure 6A). Further comparison of ICAM-1 and E-selectin
expression in IFNb- and vehicle-treated MCAO/R mice
revealed that IFNb abolished ischemia-induced upregulation
of ICAM-1 and E-selectin in the ipsilateral hemispheres
(Figure 6A). Although it was previously reported that the
expression of VCAM-1 was increased in ischemic brains, we
did not observe an increase of VCAM-1 expression in
ipsilateral compared with contralateral hemispheres of stroke
mice, and IFNb treatment did not alter VCAM-1 expression in
the ischemic brain (results not shown). The effect of IFNb on
the expression of adhesion molecules was also studied in the
brain endothelial cell line bEnd.3. bEnd.3 cells were activated
with TNFa in the absence or presence of IFNb, and the
expression of adhesion molecules was measured at mRNA
and protein levels. TNFa upregulated ICAM-1 and E-selectin
expression at both mRNA and protein level and IFNb inhibited
TNFa-induced ICAM-1 and E-selectin upregulation (Figure 6B
and 6C). In addition, IFNb reduced TNFa-induced surface P-
selectin expression (Figure 6D). Although TNFa upregulated
VCAM-1, IFNb did not affect VCAM-1 expression (data not
shown). Altogether, our results demonstrate that IFNb
inhibited the upregulation of adhesion molecules in the
ischemic brain and in brain endothelial cells.
IFNb Suppresses Chemokine and Matrix
Metallopeptidase 9 Production in Ischemic Brains
Chemokines produced in the ischemic brain facilitate the
recruitment of peripheral immune cells to the site of injury.
Chemokines such as CCL2/3, essential for monocyte/
macrophage recruitment, and CXCL3, essential for neu-
trophils recruitment, are highly induced in the ischemic
brain.29–31 In addition, matrix metallopeptidase (MMP)-9
released during ischemic injury compromises BBB integrity
and facilitates CNS inﬁltration of inﬂammatory immune
cells.32 To investigate whether IFNb regulates chemokines
and MMP-9 production in the ischemic brain, we compared
the expression of CCL3, CXCL3, and MMP-9 in vehicle- and
IFNb-treated MCAO/R mice. The expression of CCL3, CXCL3,
and MMP-9 was dramatically increased in the ipsilateral but
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not contralateral hemispheres (Figure 7A). Importantly, IFNb
treatment impaired ischemia-induced CCL3, CXCL3, and
MMP-9 expression in the ischemic brain (Figure 7A). We
further investigated the effect of IFNb on chemokines and
MMP-9 production in MG, major producers of these inﬂam-
matory mediators during brain ischemia. Similar to the in vivo
results, IFNb reduced CCL3, CXCL3, and MMP-9 expression in
LPS-activated MG (Figure 7B and 7C).
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Figure 6. Interferon (IFN)b inhibits the upregulation of adhesion molecules in vivo and in vitro. A, RNA
was extracted 24 hours after reperfusion from sham control, vehicle-, and IFNb-treated middle cerebral
artery occlusion/reperfusion (MCAO/R) mice (n=7/group) and analyzed for expression of E-selectin and
ICAM-1 by quantitative polymerase chain reaction (Q-PCR). Data are presented as the group meanSEM. B
through D, bEnd.3 cells were pretreated with IFNb with different concentration (10 to 1000 U/mL) for
1 hour followed by tumor necrosis factor (TNF)a (50 ng/mL) for 1 hour. mRNA expression of E-selectin and
ICAM-1 was determined by Q-PCR (B). bEnd.3 cells were pretreated with IFNb (1000 U/mL) for 1 hour
followed by TNFa (50 ng/mL) for 4 hours. The surface expression of ICAM-1, E-selectin, and P-selectin was
determined by FACS (C and D). Data are the representative results of 3 independent experiments.
***P<0.001 by 1-way ANOVA with Bonferroni’s multiple comparison test.
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Discussion
The effect of IFNb in cerebral ischemia, reported in a rather
limited number of publications, is still controversial. In a study
of transient focal ischemia in rat, IFNb failed to show a
protective effect,33 whereas 3 other studies reported bene-
ﬁcial effects on systemic or intracerebroventricular adminis-
tration of IFNb in a rabbit model of thromboembolic cerebral
ischemia34 and in rat and mouse models of transient MCAO/
R.35,36 The only mechanism identiﬁed to date is the inhibitory
effect of IFNb on MMP-9 production resulting in reduced CNS
inﬁltration of monocytes and neutrophils.36 In this study, our
aim was to better understand the protective effects of IFNb in
ischemic stroke, with the ultimate goal of developing an IFNb-
based therapeutic strategy for the treatment of ischemic
stroke.
We used the mouse model of MCAO/R to study the effect
of IFNb treatment in cerebral ischemia. IFNb was adminis-
tered systemically either before or after MCAO/R and the
effect was evaluated on days 2 and 4 post ischemia. IFNb
administration 3 hours before MCAO/R resulted in a 64%
reduction in infarct volume. IFNb administration 3 hours post
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Figure 7. Interferon (IFN)b suppresses chemokine and matrix metallopeptidase (MMP)-9 expression in
the ischemic brain and in primary microglia (MG). A, RNA from brains of sham controls, vehicle-, and IFNb-
treated middle cerebral artery occlusion/reperfusion (MCAO/R) mice (n=7/group) was extracted. The
expression of CCL3, CXCL3, and MMP-9 was determined by quantitavie polymerase chain reaction (Q-PCR).
Data are presented as the group meanSEM. B and C, Primary MG were pretreated with IFNb (1000 U/
mL) for 1 hour and stimulated with LPS (100 ng/mL) or TNFa (20 ng/mL)+PGE2 (106 mol/L) followed by
Q-PCR analysis for CCL3/CXCL3, and MMP-9. Data are the representative results of 3 independent
experiments. **P<0.01, ***P<0.001 by 1-way ANOVA with Bonferroni’s multiple comparison test.
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ischemia, which is the therapeutically relevant regimen, still
reduced infarct volume on day 2 by 54%. Moreover,
postischemia administration of IFNb also prevented the
increase in infarct volume at later time points, with 55%
reduction in infarct volume on day 4. The protective effect of
IFNb was mediated through IFNAR since attenuation of the
ischemic infarct by IFNb was not observed in Ifnar1/ mice.
Interestingly, in contrast to a previous report,35 in our
experiments, Ifnar1/ mice subjected to MCAO/R displayed
a slightly larger infarct size than did WT mice (17.62.0
versus 15.91.2), suggesting that endogenous IFNb might
play a protective role in ischemia-induced brain injury.
Collectively, our results demonstrate that IFNb-mediated type
I IFN receptor activation confers both short-term and long-
term protective effects against ischemic stroke. The short-
term effects are probably mediated through inhibition of MG
activation, whereas reduction in the recruitment of peripheral
immune cells such as neutrophils, monocytes/macrophages,
CD4+ T cells, and cd T cells could mediate the long-term
beneﬁcial effects of IFNb.
MG, the resident immune cells in brain, are rapidly
activated in response to ischemic injury and trigger an
innate immune response characterized by increased phago-
cytosis and production of inﬂammatory mediators and
MMPs, leading to BBB damage.37 Subsequently, peripheral
inﬂammatory immune cells inﬁltrate the ischemic brain,
resulting in secondary damage. We observed MG activation
24 hours post injury and increased inﬂammatory cell
inﬁltration into the ischemic brain 48 hours post reperfu-
sion. In the ischemic brain, MG exhibited a high level of
Iba1 expression and a large size of soma, characteristic of
the activated MG phenotype. In sharp contrast, MG from
IFNb-treated MCAO/R mice displayed lower levels of Iba1
and a smaller size of soma, similar to sham controls. The
inhibitory effect of IFNb on MG activation is related to a
signiﬁcant reduction in the expression of proinﬂammatory
cytokines TNFa, IL-1b, IL-23p19, and IL-6 in the ischemic
brain. We documented a direct effect of IFNb on MG-
derived proinﬂammatory cytokines in cultures of LPS-
stimulated primary MG, which is consistent with a previous
study showing IFNb reduced MG activation in cerebellar
organotypic cultures.38
The reperfusion-induced secondary brain injury is mediated
primarily by peripheral immune cells inﬁltrating the ischemic
CNS. The inﬂux of inﬂammatory immune cells is facilitated by
the upregulation of adhesion molecules including E-selectin, P-
selectin, ICAM-1, and VCAM-1 on brain endothelial cells after
brain ischemia.27,28 Our results show that treatment with IFNb
signiﬁcantly reduces inﬂammatory cell inﬁltrates, suggesting
that IFNb might inhibit the upregulation of adhesion molecule
expression on endothelial cells in the ischemic brain. Thus far,
the effect of IFNb on the expression of adhesion molecules has
been only partially studied with inconsistent results. Makar
et al39 showed that IFNb suppressed ICAM-1 expression in
experimental autoimmune encephalomyelitis. In contrast,
Veldhuis et al36 showed that subcutaneous IFNb administra-
tion did not suppress ischemia-induced ICAM-1 upregulation
on brain endothelial cells in a rat stroke model. Our results
show that IFNb intravenous administration suppresses
ischemia-induced upregulation of ICAM-1 and E-selectin in
the ischemic brain of MCAO/R mice. The regulatory effect of
IFNb on the expression of adhesion molecules is further
supported by our in vitro study with the bEnd.3 cell line, in
which TNFa-induced upregulation of ICAM-1, E-selectin, and P-
selectin is suppressed by IFNb. The discrepancy between our
results and those of Veldhuis et al might be because of
differences in the routes of IFNb administration. Presumably,
intravenous administration would deliver IFNb more efﬁciently
than s.c. administration allowing sufﬁcient IFNb to access the
brain microvasculature and suppress ischemia-induced upreg-
ulation of adhesion molecules.
Chemokines, in addition to adhesion molecules, are
required for recruiting leukocytes. During ischemic injury,
chemokines such as CCL2/3 and CXCL3 are released and
promotes leukocyte recruitment.40–44 In line with previous
ﬁndings, our results show that CCL3 and CXCL3 are
upregulated in the ischemic brain. Moreover, we show for
the ﬁrst time that IFNb inhibits CCL3 and CXCL3 expression
in the ischemic brain. CCL3 and CXCL3 function in the
recruitment of monocytes/macrophages and neutrophils,
respectively, and the IFNb-induced decrease in CCL3 and
CXCL3 expression correlates with reduced inﬁltration of
monocytes/macrophages and neutrophils in the ischemic
brain of IFNb-treated MCAO/R mice.
The study by Shichita and colleagues demonstrated that IL-
17-producing cd T cells play a pivotal role in ischemic stroke
pathogenesis.26 Although IL-17–deﬁcient mice developed
brain infarct at the early phase (day 1), the infarct did not
enlarge during the delayed phase (day 4) of ischemic stroke,
suggesting that IL-17 plays a pathogenic role during the
delayed phase. Moreover, the study also demonstrated that
cd T cells activated by IL-1b and IL-23 were the major
producers of IL-17 during ischemic stroke and were respon-
sible for the exacerbation of brain injury during the delayed
phase of ischemia. Our results show that IFNb attenuates
brain infarct size at the delayed phase (day 4), suggesting that
IFNb might suppress cd T-cell inﬁltration. We observed a large
increase in cd T-cell numbers in the ischemic brain on day 4.
More importantly, IFNb signiﬁcantly decreased the number of
cd T cells in the ischemic brain. Although we did not
speciﬁcally measure IL-17 production by CNS-inﬁltrating cd T
cells, the expression of IL-1b and IL-23 in the ischemic brain
was inhibited by IFNb, which would ultimately result in
decreased recruitment to and activation of IL-17–producting
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cd T cells in the ischemic brain. To the best of our knowledge,
this is the ﬁrst report that one of the mechanisms for the
protective effect of IFNb in ischemic stroke involves the
reduction in cd T-cell inﬁltration during brain ischemia.
In summary, here we demonstrate that IFNb reduces
ischemic brain infarct through its anti-inﬂammatory effects.
Several molecular mechanisms were identiﬁed in our current
study. First, IFNb reduces CNS inﬁltration of inﬂammatory
cells, including monocytes/macrophages, neutrophils, CD4+ T
cells, and cd T cells. Second, IFNb suppressed the expression
of inﬂammatory cytokines, chemokines, MMP-9, and adhesion
molecules in the ischemic brain. Finally, IFNb inhibited
ischemia-induced MG activation. Current American Heart
Association Stroke Council guidelines for the treatment of
patients with acute ischemic stroke include administration of
tissue plasminogen activator intravenously within 3 hours of
the ischemic attack. Although this treatment reduces neuro-
logical deﬁcits and improves functional outcomes,45 it also
increases reperfusion damage. This is primarily due to the
recruitment of inﬂammatory immune cells to the CNS through
the combined activity of MMPs, chemokines, and inﬂammatory
cytokines that affect both the BBB and the peripheral immune
cells.46,47 Therefore, through its multiple effects, including
inhibition of proinﬂammatory cytokines, chemokines, and
MMP-9, reduction in inﬂammatory cell recruitment to the CNS,
and inhibition of microglia activation, IFNb is a potential
therapeutic agent targeting the reperfusion damage subse-
quent to the treatment with tissue plasminogen activator.
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